In a significant advancement in the treatment of eye diseases, the U.S. Food and Drug Administration (FDA) has approved Genentech’s Vabysmo (faricimab-svoa) 6.0 mg single-dose prefilled syringe (PFS) for the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). This approval marks a pivotal development […]
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that the first patients with diabetic retinopathy have been treated in the Phase 3 GLOW2 study of tarcocimab tedromer. This milestone marks a significant advancement in the ongoing research and development efforts aimed at combating retinal diseases. Key […]
EyePoint Pharmaceuticals, Inc., committed to innovative therapeutics for serious retinal diseases, today disclosed the top-line results of the Phase 2 PAVIA clinical trial for DURAVYU (previously known as EYP-1901). This trial evaluated DURAVYU in patients with non-proliferative diabetic retinopathy (NPDR), revealing that while the treatment exhibits a biologic effect and a favorable safety profile, it […]
Glaukos acquisition of Avedro : Glaukos Corporation, a California-based ophthalmic medical technology and pharmaceutical company, has completed its previously announced acquisition of Avedro. Based in Waltham, Massachusetts, Avedro is a hybrid ophthalmic pharmaceutical and medical technology company, which is focused on treating corneal disease and disorders and enhancing vision to decrease dependency on eyeglasses or […]